Delta Asset Management LLC TN Sells 618 Shares of Becton, Dickinson and Company (NYSE:BDX)

Delta Asset Management LLC TN lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,835 shares of the medical instruments supplier’s stock after selling 618 shares during the period. Becton, Dickinson and makes up about 2.6% of Delta Asset Management LLC TN’s portfolio, making the stock its 15th largest holding. Delta Asset Management LLC TN’s holdings in Becton, Dickinson and were worth $17,407,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Guardian Life Insurance Co. of America lifted its stake in Becton, Dickinson and by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after purchasing an additional 6 shares during the last quarter. Family Firm Inc. lifted its stake in Becton, Dickinson and by 0.5% in the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after purchasing an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC lifted its stake in Becton, Dickinson and by 0.4% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 6 shares during the last quarter. Wellington Shields & Co. LLC lifted its stake in Becton, Dickinson and by 0.3% in the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock valued at $496,000 after purchasing an additional 7 shares during the last quarter. Finally, Northstar Group Inc. lifted its stake in Becton, Dickinson and by 0.3% in the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after purchasing an additional 9 shares during the last quarter. 86.01% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://weekherald.com/2017/11/15/delta-asset-management-llc-tn-lowers-stake-in-becton-dickinson-and-company-bdx.html.

In other Becton, Dickinson and news, EVP Linda M. Tharby sold 4,695 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the transaction, the executive vice president now owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders sold 47,038 shares of company stock valued at $9,480,225 in the last quarter. Corporate insiders own 1.40% of the company’s stock.

Several research firms have recently issued reports on BDX. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $210.00 price target on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target for the company in a research note on Tuesday, October 31st. Cowen and Company reiterated a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research report on Monday, August 14th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $213.47.

Shares of Becton, Dickinson and Company (BDX) opened at $220.46 on Wednesday. The company has a market cap of $50,064.30, a PE ratio of 23.18, a price-to-earnings-growth ratio of 1.72 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $225.23.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.12 earnings per share. equities analysts forecast that Becton, Dickinson and Company will post 10.63 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply